Johnson & Johnson (JNJ)

$265.77 -4.23 (-1.57%)
Market Cap 658.24B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 25.14
Forward PE 23.51
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 7,124,918
Avg Vol 7,997,160
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 65%
Beta 0.24
Analysts Strong Sell
Price Target $275.42

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Gebinator
Gebinator Aug. 27 at 2:38 PM
$SLS $JNJ
3 · Reply
greenrockk
greenrockk Aug. 27 at 2:35 PM
$JNJ easy close at 270
0 · Reply
Wallstfan
Wallstfan Aug. 27 at 2:08 PM
$JNJ added $264 and change to my IRA
0 · Reply
NRG8
NRG8 Aug. 27 at 12:57 PM
$AVGO $V $MA $JNJ $ABBV Do you know of a more undervalued company than BZUN which is profitable, growing and has low debt? BZUN share price is $2.9 and today the company has raised FY28 forecast EPS to $1.79 .
0 · Reply
Galarius
Galarius Aug. 27 at 12:44 PM
$JNJ $SLS interesting
1 · Reply
Joshoowa
Joshoowa Aug. 27 at 12:14 PM
$SLS https://www.jnj.com/health-and-wellness/what-is-acute-myeloid-leukemia $JNJ added this to their website August 17th. Hmmmm. Everything here points to GPS and an acquisition of SLS. Good chance it could be them buying. They don't do things without reason.
1 · Reply
Parlandoconme
Parlandoconme Aug. 27 at 11:11 AM
$TOMZ Buy time. Easily beating revenue estimates in Q3 according to an insider named Ray. $JNJ $STE $SPCX
0 · Reply
clan
clan Aug. 27 at 5:36 AM
$MNKD $UTHR Oh, btw, Mannkind's Nintedanib DPI, in Ph 2 trial, does NOT have any adverse events! 😀 ... unlike the current 💩-causing OFEV. Made in the U.S.A.! 💪🇺🇲💪 👀 $SPY 👀 $QQQ 👀 $JNJ 👀
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 27 at 3:13 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Gebinator
Gebinator Aug. 27 at 2:54 AM
$SLS If it is not Johnson & Johnson ($JNJ), which will it be? (if not on the list 👇 please specify in comments):
0 · Reply
Latest News on JNJ
China approves J&J's oral psoriasis pill, says drugmaker

Aug 27, 2026, 5:42 AM EDT - 10 hours ago

China approves J&J's oral psoriasis pill, says drugmaker

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Aug 24, 2026, 7:12 PM EDT - 2 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

US FDA expands approval for J&J's drug for rare blood disorder

Aug 24, 2026, 6:33 PM EDT - 2 days ago

US FDA expands approval for J&J's drug for rare blood disorder

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Aug 24, 2026, 12:20 PM EDT - 3 days ago

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

2026-08-19T22:09:27.000Z - 7 days ago

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

LIN

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

2026-08-17T10:16:04.000Z - 10 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 13 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 10, 2026, 4:27 PM EDT - 17 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

2026-08-07T19:33:43.000Z - 20 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

Aug 6, 2026, 6:23 PM EDT - 20 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

2026-08-06T10:48:29.000Z - 21 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 4:05 PM EDT - 23 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 4, 2026, 8:45 AM EDT - 23 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 24 days ago

Johnson & Johnson Transcript: Investor update

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 25 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 6:13 PM EDT - 4 weeks ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:42 PM EDT - 4 weeks ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 4 weeks ago

Johnson & Johnson lowers 2026 profit forecast

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 5:28 PM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 4 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 4:31 PM EDT - 4 weeks ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 4 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 1:03 AM EDT - 4 weeks ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 4 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 9:29 PM EDT - 4 weeks ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:47 PM EDT - 4 weeks ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 6:31 PM EDT - 4 weeks ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

Jul 27, 2026, 5:45 AM EDT - 4 weeks ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23, 2026, 8:30 AM EDT - 5 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 4:33 PM EDT - 5 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:21 AM EDT - 5 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 22, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jim Cramer says this old-school investing concept still wins — even in the AI boom

Jul 21, 2026, 6:30 PM EDT - 5 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 6 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 6 weeks ago

DePuy Synthes Acquires Expanding Innovations™

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 6 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 6 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 6 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 6 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 6 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 6 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 7 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Gebinator
Gebinator Aug. 27 at 2:38 PM
$SLS $JNJ
3 · Reply
greenrockk
greenrockk Aug. 27 at 2:35 PM
$JNJ easy close at 270
0 · Reply
Wallstfan
Wallstfan Aug. 27 at 2:08 PM
$JNJ added $264 and change to my IRA
0 · Reply
NRG8
NRG8 Aug. 27 at 12:57 PM
$AVGO $V $MA $JNJ $ABBV Do you know of a more undervalued company than BZUN which is profitable, growing and has low debt? BZUN share price is $2.9 and today the company has raised FY28 forecast EPS to $1.79 .
0 · Reply
Galarius
Galarius Aug. 27 at 12:44 PM
$JNJ $SLS interesting
1 · Reply
Joshoowa
Joshoowa Aug. 27 at 12:14 PM
$SLS https://www.jnj.com/health-and-wellness/what-is-acute-myeloid-leukemia $JNJ added this to their website August 17th. Hmmmm. Everything here points to GPS and an acquisition of SLS. Good chance it could be them buying. They don't do things without reason.
1 · Reply
Parlandoconme
Parlandoconme Aug. 27 at 11:11 AM
$TOMZ Buy time. Easily beating revenue estimates in Q3 according to an insider named Ray. $JNJ $STE $SPCX
0 · Reply
clan
clan Aug. 27 at 5:36 AM
$MNKD $UTHR Oh, btw, Mannkind's Nintedanib DPI, in Ph 2 trial, does NOT have any adverse events! 😀 ... unlike the current 💩-causing OFEV. Made in the U.S.A.! 💪🇺🇲💪 👀 $SPY 👀 $QQQ 👀 $JNJ 👀
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 27 at 3:13 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Gebinator
Gebinator Aug. 27 at 2:54 AM
$SLS If it is not Johnson & Johnson ($JNJ), which will it be? (if not on the list 👇 please specify in comments):
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 26 at 6:50 PM
$AZN $JNJ $PFE $SLS Part 2. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 26 at 6:43 PM
$SLS $JNJ $AZN $PFE picture is worth 1000 words and the winner is? ✌️🙏❤️‍🩹
0 · Reply
Outcomes
Outcomes Aug. 26 at 5:59 PM
$IBRX $MRNA $MRK $PFE $JNJ Sadly, ‘Turbo-cancers’ don’t discriminate. mRNA BAD. Dr. PSS knows. Dr. Jim Kim knows. SAVE THE CHILDREN. 🙏🏻 One of Dolly Parton’s passions. Moderna should be donating millions to Dolly’s charities. https://x.com/valerieanne1970/status/2092660136221323564?s=46
0 · Reply
Heliosphere
Heliosphere Aug. 26 at 3:47 PM
$CMPX $BMY $JNJ $MRK $AZN Should buy $CMPX!
1 · Reply
TalkMarkets
TalkMarkets Aug. 26 at 3:23 PM
Is US Government Debt Getting Riskier? Also Mentions: $MSFT $JNJ https://talkmarkets.com/article/is-us-government-debt-getting-riskier-1787757774
0 · Reply
Estimize
Estimize Aug. 26 at 2:18 PM
Wall St is expecting 2.90 EPS for $JNJ Q3 [Reporting 10/20 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 26 at 4:00 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Slabby999wrld
Slabby999wrld Aug. 25 at 8:08 PM
$NVAX $MRNA $PFE $JNJ what are yall doing not buying out nvax? Whoever does first is going to be king
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 25 at 7:25 PM
#Humorme #please ? $LLY $JNJ $MRK $MRNA
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 25 at 6:37 PM
$JNJ $PFE $SLS I used to be able to call John F. From IR for basic general inquiries without any problems. Now my phone calls go through straight to his voicemail and not even a courtesy response back. Not a single call back in almost 2 months. ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 25 at 6:30 PM
$SLS $139 Million in cash on hand. 13 Full Time Employees. Change of Control filed. Not a single Medical Conference scheduled. I am just waiting for the T1 halt to find out the final suitor $JNJ with Cavanaugh taking over September 1, 2026 or $PFE Bourla. ✌️🙏❤️‍🩹👏
0 · Reply
BarkingPuppy
BarkingPuppy Aug. 25 at 6:16 PM
$ELTP $WEN $GME $JNJ Miss me??? I have been working a double at Wendys. BIG BUYER MOVING IN TODAY FOR ELTP.... Elite Pharmaceuticals is also advancing products that could sustain growth beyond its recent launches. The company filed an ANDA (Abbreviated New Drug Application) for an undisclosed anticoagulant and reported a successful pivotal bioequivalence study for an anticonvulsant candidate. Its generic OxyContin ER product also remains under FDA review. Progress across these programs could further expand and diversify ELTP's commercial portfolio over time.
2 · Reply